Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience
Jamie Walker, Daryle Deering, Bruno Hamish Unger
Journal of Psychoactive Drugs May 22, 2026 Peer reviewed DOI: 10.1080/02791072.2026.2673843 via OpenAlex
Summary
Ibogaine, a psychoactive substance legally prescribed in New Zealand, was explored for its effects on opioid-dependent individuals undergoing detoxification. Ten participants reported experiences of rapid detoxification, improved mood, and reduced anxiety, although some experienced relapse. Key factors for positive outcomes included thorough preparation, medical screening, and post-treatment support. The study highlights the potential of ibogaine in treating opioid dependence and suggests areas for clinical practice and policy improvement.
Study at a glance
| Design | qualitative collective case study |
|---|---|
| Sample size | 10 |
| Population | opioid-dependent individuals using ibogaine for detoxification |
| Key finding | Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence. |
Abstract
Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was used to examine the experiences and motivations of 10 opioid-dependent individuals who used ibogaine for opioid detoxification. Participants were recruited through ibogaine networks, OST services, and snowball sampling. Semi-structured interviews were conducted and analyzed using an inductive thematic analysis approach, informed by an interpretive, experiential framework. Analysis focused on how participants understood their motivations, treatment processes, safety practices, and post-treatment outcomes. Seven themes were identified: "Desperation to be opioid free," "motivations for using ibogaine," "safety conscious and support seeking," "improving ibogaine practices," "effects of treatment on depression and anxiety," "effects of treatment on dependence," and "the spiritual effect." Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases. Preparation, medical screening, and post-treatment psychosocial support were critical to positive outcomes. This study adds to the literature by documenting experiences of ibogaine use, with implications for clinical practice, policy, and future research.